Protect from BrEaST cancer and CARdiovascular disEase

Protect from BrEaST cancer and CARdiovascular disEase - BEST CARE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046767

Enrollment

150

Registered

2022-01-29

Start date

2021-04-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 20 years or older Breast cancer patients who plans to receive anthracycline chemotherapy Breast cancer patients who previously received anthracycline chemotherapy and will be receiving other chemotherapy regimen

Exclusion criteria

Exclusion criteria: Patients who are considered difficult to perform cardiac ultrasound Patients without written consent Patients who were considered not appropriate to include in the study by their treating physician

Design outcomes

Primary

Measure	Time frame
The predictive value of GDF-15 in CTR-CVT	—

Secondary

Measure	Time frame
The predictive value of GDF-15 in CTRCD The predictive value of GDF-15 in all cause mortality The association between GDF-15 levels and breast cancer	—

Countries

Japan

Contacts

Public ContactEri Kato

Kyoto University Hospital Cardiology

erikato@kuhp.kyoto-u.ac.jp075-751-3111

Outcome results